MAP2K1 and hepatocellular carcinoma: MEK1 phosphorylates the ERK1/2 proteins in the RAS/RAF/MEK pathway (Figure 2).[41] MAP2K1 amplification has been reported in 2% of HCC samples.[38] The relationship between MEK amplification and sensitivity to MEK inhibitors is unknown.